Skip Navigation
Johns Hopkins Bloomberg School of Public Health
   

IVAC Blog

 

By Lois Privor-Dumm and Huma Khawar.

This article was originally published on Vaccineswork and is cross-posted here with permission.

PolioIPVPakistan3

Photo: UNICEF/PAK 2015/Asad Zaidi

In Nigeria and around the world, citizens, governments, doctors, and parents are fighting polio – and they’re winning. After nearly 30 years of polio eradication efforts, the end is in sight. In 1988, the year the World Health Assembly (WHA) resolved to eradicate polio, there were an estimated 350,000 polio cases globally; last year there were only 359, and this year cases so far are down by 75%.Misbau Lawan Didi leads a club he wants to eliminate. As president of the Polio Survivors Association, he is committed to not only end polio in Nigeria but to eradicate it from the planet. “We are determined,” he says, “to ensure that our members are no more.”

Polio has eluded us for decades. There have been plenty of starts and stops and lots of excitement about the polio eradication effort.

So what makes this time different?

Communities around the world are mobilizing, and momentum is building. Last month, one of the remaining three endemic countries, Nigeria, passed the one year mark without a single case of wild poliovirus. Once the final samples are tested and cleared, the World Health Organization should even be able to declare Nigeria a non-endemic country. Many thought it wouldn’t be done.  

Now, Pakistan is embarking on one important step in its fight against polio and implementing the endgame strategy with introduction of the inactivated polio vaccine (IPV) across the country. It will take determination and sustained effort to ensure that it can be done – and with a decentralized health system, years of war, and continued threats against health workers, it will be no easy feat.

Step by step, progress is being made. We are on the brink of an unprecedented accomplishment. Yet, public health experts warn “the last mile” will be the hardest. Ending transmission of the virus in every country will take a focused effort and the use of every available tool against the disease. The Polio Eradication and Endgame Strategic Plan was developed to provide countries with a roadmap to help navigate this challenge. The plan calls on countries to make three important changes to their immunization efforts: 1) to introduce one dose of (IPV) into routine immunization schedules, 2) to strengthen routine immunization, and 3) to eventually withdraw oral polio vaccine (OPV).

The first phase of this plan, the introduction of IPV, is well underway. While there was initial concern over an accelerated timeline, communities and governments around the world have risen to the challenge. The introduction of IPV will be one of the fastest rollouts in history. Out of 126 oral polio vaccine (OPV) only using countries, 30 have now introduced. Today, on August 20th, Pakistan launches its nationwide rollout, which is no small feat. The significance of this rollout is monumental.  

PolioIPVPakistan2

Photo: UNICEF/PAK 2015/Waseem Niaz

Introducing a new vaccine involves hundreds of technical and logistic details. There are budget considerations, procurement, storage and transport of vaccines, training of health workers, and communication with parents. Countries need to assess their systems and strengthen necessary components. In Nigeria, for example, communicating with the public was particularly important as skepticism about the polio vaccine halted past efforts. When Nigeria introduced the new polio vaccine in February of this year, community and religious leaders were active in the outreach to parents. In markets and in mosques, the public was told about the importance of immunization and using the IPV vaccine in the battle against polio. In February, when Nigeria became the first polio endemic country to introduce the vaccine, it was widely accepted by parents.

We are down to the last three polio endemic countries – Nigeria, Pakistan and Afghanistan – and now there is even greater hope.  Last year, there were no new members of Nigeria’s Polio Survivors Association as the country did not have any cases of the disease. Work in Nigeria is far from over, but the effort is paying off: two more years without a reported case and Nigeria can be certified as polio free.

The same can be true in Pakistan and the other countries where communities are hard at work to protect their children and eradicate this virus. This time it really can be different. Pakistan, is your time now?

Lois Privor-Dumm is the Director of Policy Advocacy & Communication at IVAC at the Johns Hopkins Bloomberg School of Public Health. Huma Khawar is a freelance journalist and consultant based in Islamabad who works with stakeholders on the ground in Pakistan to advocate for new vaccines through the Vaccine Implementation Technical Advisory Consortium (VITAC), a project of the Gavi Alliance.

With the help of a long list of partners and supporters, IVAC has developed a portfolio of advocacy materials supporting IPV introduction, which can be found here. Inquiries can be directed to Lois Privor-Dumm at lprivor1@jhu.edu.

By Dr. Anne von Gottberg, Respiratory and Meningeal Pathogens Research Unit, National Institute for Communicable Diseases

This article was originally published on www.vaccineswork.org and is cross-posted here with permission.

If you had looked at South Africa’s invasive pneumococcal disease (IPD) surveillance data before 2002, you would have never guessed that one day that data would land on the pages of the New England Journal of Medicine

Even I thought such a feat was impossible. Surveillance for IPD was passive and patchy – certainly not the kind of data you could use to examine trends or measure impact.  In 2002, experts in pneumonia and respiratory disease suggested that we completely revamp the system: start measuring antimicrobial resistance and serotypes, obtain clinical data from cases to explore risk factors for resistance.  Although this was long before the pneumococcal conjugate vaccine (PCV) was introduced, we knew any investments we made in the surveillance system now would pay huge dividends later, and possibly allow us to measure the impact of PCV introduction.

Noluthando Duma works in the lab

An example of disease surveillance activities. Here, Noluthando Duma works in the lab. Photo: NICD.

Revamping a national surveillance system was not an easy task.  Our institute managed the process - from employing surveillance staff throughout the country to collecting data - and we had many, many challenges.  This project seemed so unusual, so impossible, that it was difficult to convince anyone to join us.  We would interview surveillance officers at remote regional sites who wondered how they could report to a central office in Johannesburg, given that they had never even been there; they couldn’t imagine how such a big, unwieldy national program could ever work. We would answer their questions with what I hoped sounded like confidence, but the truth was that we were figuring out the answers as we went along.

Despite these human resource challenges, we charged ahead, but it was a slow-and-steady race.  At our national surveillance officer and principle investigator meetings, we had to bring together key stakeholders to discuss the surveillance network.  We had to get buy-in on the methods, the case definitions, the flow of data, and sharing of information, and then we had to hire staff to operationalize our ambitious plans. Many new hires had never been on an airplane before, and some had never seen the ocean – the surveillance network really made South Africa smaller, bringing people together in the “new South Africa” in ways that I could not have predicted. So we anxiously booked window seats, made time for quick excursions to the beach, and hoped for the best. And although we had our fair share of hiccups along the way, our small team continued to grow, the years passed, and we kept on finding ways to silence the naysayers!

Meanwhile, things did not stay still around us.  The South African government suddenly found the political will to tackle the HIV/AIDS epidemic, and with a tremendous effort, the government and civil society rapidly improved care of HIV-infected pregnant women, HIV-infected children, and adults in general.  With these sudden improvements in healthcare, IPD also changed, making it more difficult to attribute any declines to the vaccine, even with the new surveillance system.  But through a series of discussions with local and international colleagues and friends, countless conference calls, and careful review of the data, it finally became possible to tell the story that was in the data, collected for so many years by our dedicated surveillance teams.

southafricasurveillance

Colleague Kedibone Ndlangisa conducting lab work. Photo: NICD

Last week, as experts and decision makers gathered in Kenya to discuss the results of various PCV impact studies from across Africa – all showing significant reductions in pneumococcal disease after the introduction of the vaccine – I was reminded of how far we had come on our journey and the many lessons learned on our path. 

By maintaining our slow-and-steady approach remembering to “ask a friend” when we were stumped, and above all continuing to plow on in the face of challenges, we were able to turn data that at first glance may have looked like a mess into a meaningful and robust assessment of the impact of PCV. 

This study is part of the the Vaccine Implementation Technical Assistance Consortium (VITAC) - a collaboration of PATHCDC, and IVAC - supports the achievement of the mission to save lives, prevent disease, and promote health through timely and equitable access to new and underused vaccines. VITAC is focused on accelerating the introduction and sustained use of vaccines by creating the evidence base, advocating for evidence-driven decision making, and establishing a platform for countries to assess the resources needed for sustained and optimal use of vaccines.

This article was originally published on Global Health Now and is cross-posted here with permission.

By: Dr. Mathuram Santosham

ChildUPIndia
A healthy child in Uttar Pradesh, India, 2010 © Gates Foundation

World Immunization Week provides a moment to reflect on the tremendous progress in reducing one of the world’s leading killers of children—diarrhea.

While oral rehydration solution has significantly reduced diarrheal disease mortality since its adoption in 1978, diarrhea continues to be a major cause of childhood illness and death globally. Rotavirus, the most common cause of severe diarrhea, is responsible for approximately 40% of all diarrhea hospitalizations and hundreds of thousands of deaths in children under 5.

Rotavirus vaccines offer the best protection for children and are an essential part of comprehensive diarrhea control. While the WHO recommends that all countries introduce rotavirus vaccines, only 77 have done so, 34 of which are Gavi-eligible countries where many of the deaths occur. Unfortunately, some of the most vulnerable children and communities do not have access to the vaccine.

In particular, Asia has lagged in introducing rotavirus vaccines, even though it accounts for more than 40% of global rotavirus deaths. To date, no country in the region has introduced the vaccine into its national immunization program.

While dramatic reductions in deaths from childhood diarrheal disease have been achieved in Bangladesh, there are still more than 2.4 million rotavirus cases each year. It causes 2 out of every 3 diarrhea-related hospitalizations among children under 5. There are also serious economic consequences. One episode of rotavirus costs the average Bangladeshi family about USD $80 in direct hospital costs, a significant portion of average monthly income.

In neighboring India, where rotavirus is equally ubiquitous, the disease poses a significant financial burden to families and the country’s economy. Studies have shown that a hospitalization for rotavirus could potentially push a family into poverty or keep them there. Depending on the level of care, the total cost of a rotavirus hospitalization could range anywhere from nearly $32 to more than $135, equal to up to 2 months of income for an average Indian family. Rotavirus also burdens the healthcare system with the high cost of hospitalizations and outpatient visits. One study estimated that hospitalizations and outpatient visits cost India approximately $78 million and $86 million each year, respectively—each more than the estimated $72 million it would cost to fund a rotavirus immunization program.

For fast-growing countries like India and Bangladesh, tackling rotavirus—which cheats children and the nation of productivity, well-being and development—should be a priority. However, the available and effective rotavirus vaccines are not yet available in the national immunization programs of either country. 

Many of my scientific colleagues in Bangladesh are making a good case to their leaders for national introduction of rotavirus vaccines. And, I’m inspired by the strides being made in India. Last July, Prime Minister Narendra Modi announced that rotavirus will be included in the Universal Immunization Programme; and just last month, the first India-made rotavirus vaccine, ROTAVAC, was launched. Now is the time to get to the finish line—the cost of delaying access to rotavirus vaccines continues to mount. Together we can close this immunization gap and virtually eliminate rotavirus.

Dr. Mathuram Santosham is the Director of the Center for American Indian Health, Chair of the ROTA Council, and Senior Advisor at the International Vaccine Access Center at Johns Hopkins Bloomberg School of Public Health. Dr. Santosham and his colleagues won an Honorable Mention in GHN's Untold Global Health Stories Contest for their submission of rotavirus in Bangladesh and India. GHN will feature one Honorable Mention story per month from now until the next contest in early 2016.

This article was originally published in Open Magazine and is cross-posted here with permission. 

This post is part of the #ProtectingKids blog series. Read the whole series here.PATH2015_BlogSeries

NiyaSons
Niya Zameen with her two boys outside their home in Ramsar

Niya Zameen, 33, lives with her two sons in Ramsar, in Barmer district of Rajasthan. Her village has a population of just 1,078 and is close to the India-Pakistan border. Niya has always tried to ensure that her children receive the necessary healthcare services, including vaccines, to give them a healthy start in life. Getting her children vaccinated hasn’t always been easy because of shortages of government recommended vaccines. But Niya has never given up. With the help of the local health worker, Rampatti, she made sure that her children received the necessary vaccines against measles, polio, and three doses of diphtheria-tetanus-pertussis. 

IndianBoyImmunizedOf the 1.3 million Indian children under-5 that died in 2013, pneumonia claimed more than 175,000 lives and diarrhoea caused more than 130,000 deaths. Even in cases of survival, the severe burden of illness from diarrhoea and pneumonia adversely impacts children’s growth and development. But many of these severe illnesses can be easily prevented through immunisation. The pentavalent vaccine, that prevents a deadly form of pneumonia and meningitis, is now available through government immunisation programmes in some states and the vaccine to tackle diarrhoea caused by rotavirus, will soon be rolled out.

Niya Zameen acknowledges the crucial role that Rampatti, the local health worker, plays in her life. She has provided guidance on important health decisions, including the role of vaccines in giving all children protection against preventable diseases.

Vaccine delivery is a challenge in this region, due to extremely hot weather and the difficult desert terrain. If the vaccines don’t arrive on the designated day of immunisation, Rampatti travels to the vaccine cold chain point to collect them for her village. On her return, she vaccinates children. 

IndiaHW

Every child has the right to a healthy start, and it is the responsibility of not just the government, but also of the community to ensure that all our children are timely and fully immunised.

Photos by Shikha Nayyar

GUEST BLOGGER

Matt Coles

MattColesMatt Coles serves as the Senior Program & Contract Analyst for IVAC. Prior to IVAC, he worked for the National Foundation for the Centers for Disease Control & Prevention and served as a US Peace Corps Volunteer in West Africa from 2000-2003.

This post is part of the #ProtectingKids blog series. Read the whole series here.PATH2015_BlogSeries

By: Matt Coles

This is not a not a sports article, I promise.  On Sunday, February 1st, millions of people tuned into the Super Bowl to watch the New England Patriots and Seattle Seahawks duke it out, including an incredible 4th quarter catch by Jermaine Kearse of the Seahawks and a goal line interception by Malcolm Butler to clinch the Patriots win.  One of my passions is football, but I was unable to watch the last quarter of that game.  Our three month old son was having trouble breathing.

As a parent, there are two situations in which you always take your child to the hospital – when their fever is over 100°or they are having trouble breathing.  The cough started small on Friday and only worsened over the weekend.  Finally, on Sunday night, we made the decision to head to the hospital.  My wife hurriedly made her way to the hospital, trying to beat the snow that was coming down, while I stayed back to call the neighbors to watch our daughter, who was fast asleep. 

MattsBaby
Matt's baby in the hospital

Later at the hospital, we discovered our son had Respiratory Syncytial Virus, or RSV.  This is a virus that affects breathing and, in infants, secondary infections such as bronchiolitis and pneumonia can make it more serious.  According to the Centers for Disease Control and Prevention (CDC), almost all children will have an RSV infection by their 2nd birthday.  Here in the United States, approximately 100,000 - 126,000 infants and children under the age of two are hospitalized from RSV.

RSV was new to us and, aside from short-acting prophylaxis for at-risk children, there is no vaccine on the market to prevent RSV.

I am well-informed about respiratory infections in children such as pneumonia, whooping cough, influenza, croup, and Hib.  I’m very fortunate to work at the Johns Hopkins Bloomberg School of Public Health and its International Vaccine Access Center (IVAC) – a place where I can ask my colleagues questions on childhood diseases, both from an academic and parental standpoint. Not all parents are this lucky.

As parents, we sometimes question our decisions for our children, especially when they get sick.  Should we have called the pediatrician earlier?  Will the medicine work?  Will the fever break?  It goes with the territory.

One thing we do not question is the benefits of vaccines.  I have seen firsthand the benefits of vaccines in The Gambia, where I served as a Health Volunteer with the Peace Corps from 2000-2003.  During my Peace Corp service, I worked with the Ministry of Health National Immunization Days for Polio.  We went house to house helping to vaccinate children with the oral polio vaccine (OPV) and providing Vitamin A supplementation for infants during week-long vaccine campaigns.  More than a decade later, our son’s brief battle with RSV only helped to reinforce the value I place on vaccines and the need for more, effective vaccines.

When we came home from the hospital, we also had to do breathing treatments four to five times a day to continue to loosen the mucus.  There were some sleepless nights that week, but we got through it.  The cough dissipated and like the Patriots victory, my family was also able to celebrate duking it out with RSV.  The victory photo says it all...

MattsBaby2